Loading current stock analysis…
Loading current stock analysis…
As of 2026-08-25
Sun Pharma received a favorable verdict in its U.S. antitrust litigation, affirming a settlement with Pfizer concerning competition for generic Lipitor. This was announced on August 17, 2026.
Sales have shown consistent growth, increasing from ₹29,066 crore in March 2019 to a projected ₹58,462 crore by March 2026. Net profit has also seen significant growth, rising from ₹3,208 crore in March 2019 to a projected ₹11,509 crore by March 2026. The Compounded Sales Growth over 5 years was 12%, and Compounded Profit Growth over 5 years was 17%.
Sun Pharma's borrowings have decreased significantly from ₹10,514 crore in March 2019 to a projected ₹2,362 crore by March 2025, before increasing to ₹4,627 crore by March 2026. Reserves have grown from ₹41,169 crore in March 2019 to a projected ₹83,330 crore by March 2026. Total Assets have increased from ₹64,590 crore in March 2019 to a projected ₹108,407 crore by March 2026.
As of the quarter ended June 30, 2026, Sun Pharma reported a Revenue from Operations of ₹15,299.88 crore, Earnings Per Share (EPS) of ₹12.10, and a Net Profit Margin of 18.92%. The Interest Coverage ratio was 42.12, the EBIT Margin was 27.44%, and the EBITDA Margin was 32.27%.
Recent technical anomalies include a 'Large intraday price swing' on August 17, 2026, and July 31, 2026. There was also an 'Unusually active upward session' on July 27, 2026, and a 'Downside gap' on July 22, 2026.
The daily trend is described as a 'weak downtrend' with a high confidence level, indicated by the price being below the 20-day Simple Moving Average (SMA). The weekly trend is a 'moderate uptrend' with medium confidence, as the price is above the 20-day and 50-day SMAs, and the Supertrend indicator is bullish. The current risk is assessed as 'contained risk' with a low confidence level, based on recent drawdown and price variability.
Showing 3 of 18 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹15,299.88 crore | ₹14,611.79 crore | PEAK₹15,520.54 crore | ₹14,478.31 crore | ₹13,851.40 crore |
| Profit Before Tax | ₹4,098.81 crore | ₹3,551.34 crore | PEAK₹4,227.16 crore | ₹4,167.61 crore | ₹3,172.77 crore |
| Finance Costs | ₹99.67 crore | ₹85.89 crore | ₹78.36 crore | PEAK₹99.86 crore | ₹74.80 crore |
| Exceptional Items Before Tax | -₹204.09 crore | PEAK₹0.0 | -₹489.48 crore | PEAK₹0.0 | -₹818 crore |
| Comprehensive Income For The Period | ₹4,410.38 crore | ₹4,213.03 crore | ₹4,161.69 crore | PEAK₹4,540.38 crore | ₹2,420.29 crore |
| Other Comprehensive Income | PEAK₹1,509.15 crore | ₹1,503.37 crore | ₹780.52 crore | ₹1,415.43 crore | ₹127.42 crore |
Sun Pharmaceutical Industries Limited reported revenue of ₹15,299.88 crore for the quarter ended 30 June 2026, up 10.5% from the same quarter last year. Profit before tax increased 29.2% to ₹4,098.81 crore, partly driven by a reduction in exceptional charges from ₹818 crore to ₹204 crore. Excluding exceptional items, underlying profit before tax grew 7.8%, slower than revenue. Comprehensive income rose sharply due to a large other comprehensive income component.
Revenue from operations was ₹15,299.88 crore, compared to ₹13,851.40 crore in the same quarter last year, an increase of 10.5%. Sequentially, revenue rose 4.7% from ₹14,611.79 crore in the preceding quarter (Q4 FY2025-26). Over the past five quarters, revenue peaked in Q3 FY2025-26 at ₹15,520.54 crore, declined in Q4, and recovered in the current quarter.
Profit before tax (PBT) increased 29.2% year-on-year to ₹4,098.81 crore from ₹3,172.77 crore. The prior-year quarter included an exceptional charge of ₹818 crore, while the current quarter had a smaller exceptional charge of ₹204.09 crore. Adjusting for these items, PBT before exceptional items was ₹4,302.90 crore versus ₹3,990.77 crore a year ago, a growth of 7.8% — below the revenue growth rate of 10.5%. This indicates that underlying profitability did not expand as much as the headline PBT figure suggests.
Finance costs rose to ₹99.67 crore from ₹74.80 crore a year ago, a 33.3% increase, and also increased sequentially from ₹85.89 crore in Q4. Other income for the quarter was ₹723.62 crore.
Comprehensive income for the period was ₹4,410.38 crore, up 82.2% from ₹2,420.29 crore in the same quarter last year. This large increase was primarily due to a surge in other comprehensive income (OCI), which rose from ₹127.42 crore to ₹1,509.15 crore. OCI in the current quarter was nearly flat compared to the preceding quarter (₹1,503.37 crore). Net profit for the period was ₹2,901.23 crore, implying an effective tax rate of about 29.0% on the reported PBT.
Major operating costs for the quarter included cost of materials consumed (₹2,026.28 crore), employee benefit expense (₹3,227.23 crore), and depreciation, depletion, and amortisation (₹738.72 crore). Together, these three items accounted for 39.1% of revenue. Finance costs added another ₹99.67 crore.
Basic and diluted earnings per share from continuing operations were ₹12.10, up from ₹9.50 a year ago, a 27.4% increase. The EPS figures for continuing and discontinued operations are identical, indicating no material impact from discontinued operations on per-share earnings. The equality of basic and diluted EPS also points to the absence of dilutive equity instruments.
Sun Pharma’s June 2026 quarter delivered revenue growth of 10.5% year-on-year, but the 29% increase in profit before tax was significantly influenced by a reduction in exceptional charges. Underlying profit growth, excluding exceptional items, was slower than revenue growth. Comprehensive income was boosted by a large other comprehensive income component, which has been elevated in recent quarters. The company had no dilutive securities, and discontinued operations had no material effect on per-share earnings.
Exchange disclosures and regulatory announcements for Sun Pharmaceutical Industries.
Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
Sun Pharmaceutical Industries Limited is seeking shareholder approval via postal ballot and e-voting to reclassify Mr. Sudhir Vrundavandas Valia, Mrs. Raksha Sudhir Valia, and Mrs. Krishna Vrundavandas Valia from the 'Promoter Group' to the 'Public' category under SEBI Regulation 31A. The applicants collectively hold 431,753,71 shares (1.80% of paid-up capital) but are not involved in management or control, a move that will reduce promoter holding from 54.48% to 52.68% while increasing public holding to 47.32%. Shareholder voting is scheduled to open on August 28, 2026, and close on September 26, 2026, with results to be announced by September 29, 2026.
Sun Pharmaceutical Industries Limited announced a postal ballot for shareholders on August 28, 2026, with voting ending September 26, 2026, to seek an ordinary resolution for reclassifying Mr. Sudhir Vrundavandas Valia, Mrs. Raksha Sudhir Valia, and Mrs. Krishna Vrundavandas Valia from the 'Promoter Group' to the 'Public' category under SEBI LODR Regulation 31A.
Update on Lipitor Antitrust Litigation |SUBJECT: General Updates
Sun Pharmaceutical Industries Limited received no-objection letters on August 6, 2026, from the National Stock Exchange of India and BSE Limited for the reclassification of Krishna Vrundavandas Valia, Sudhir Vrundavandas Valia, and Raksha Sudhir Valia from the 'Promoter Group' to the 'Public' category, as per SEBI Listing Regulations.
Sun Pharmaceutical Industries Limited reported Q1 FY27 sales of INR 1,51,836 million, a 10.1% increase year-over-year, with EBITDA at INR 44,177 million. The company noted acquisition-related costs of INR 1,617 million for the Organon transaction, which is on track to close by early 2027. Global Innovative Medicines sales grew 12.8% to USD 351 million, while India formulations sales increased 16% to INR 54,749 million. The U.S. business reported sales of USD 427 million, a 9.7% decline, primarily due to generic product erosion.
Sun Pharmaceutical Industries Limited will hold meetings with Nirmal Bang Institutional Equities on August 10, 2026, Emkay Confluence 2026 on August 12, 2026, and Equirus Annual India Conference on August 13, 2026. The company will not disclose any Unpublished Price Sensitive Information during these meetings.
On August 5, 2026, Sun Pharmaceutical Industries Limited announced that CRISIL Ratings Limited has removed the 'Rating Watch with Developing Implications' from its long-term bank facilities and reaffirmed the rating at 'CRISIL AAA/Stable'. This follows an earlier communication on May 7, 2026, regarding the rating watch placed after an announcement on April 27, 2026.
Sun Pharmaceutical Industries Limited published newspaper advertisements on August 1, 2026, in the Financial Express (English and Gujarati) announcing their Unaudited Financial Results for the quarter ended June 30, 2026. These results are also available on the company's website.
The Board of Directors of Sun Pharmaceutical Industries Limited met on July 31, 2026, with the meeting commencing at 10:50 A.M., adjourning for a break, and concluding at 3:40 P.M. This follows a prior communication dated July 31, 2026.
Sun Pharmaceutical Industries Limited held its 34th Annual General Meeting on July 31, 2026. All resolutions presented in the notice dated July 6, 2026, were passed by shareholders with the required majority, as confirmed by the Scrutinizer's Report. The voting results and Scrutinizer's Report are available on the company's website.
Sun Pharmaceutical Industries Limited has made the audio recording of its investor earnings call, held on July 31, 2026, available on its website. This follows their prior intimation on July 14, 2026, regarding the call. The recording can be accessed via a provided link.
On July 31, 2026, Sun Pharmaceutical Industries Limited announced its Q1 FY27 financial results, reporting consolidated sales of Rs. 151,836 million, a 10.1% year-over-year increase. The company's net profit for the quarter was Rs. 28,948 million. Key highlights include strong performance in India and the Innovative Medicines segment, with global sales of Innovative Medicines reaching US$351 million, up 12.8%. The company also provided an update on its proposed acquisition of Organon & Co., noting that Organon shareholders have approved the deal, which is on track for closure in early 2027.
Sun Pharmaceutical Industries Limited held its 34th Annual General Meeting on July 31, 2026, where shareholders approved the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. Key approvals included the declaration of a final dividend of Rs. 5.00 per equity share, the re-appointment of Mr. Aalok Shanghvi, and the appointment of Dr. Andreas Busch as an Independent Director. The company reported consolidated revenues of ₹582 billion for FY26, with R&D expenditure at ₹35.5 billion.
Sun Pharmaceutical Industries Limited received approval from Brazil's ANVISA to manufacture and market semaglutide injection for type 2 diabetes. The company plans to launch the product in partnership with Hypera Pharma within days. The semaglutide injectable market in Brazil is valued at approximately USD 413 million as of June 2026.
Sun Pharmaceutical Industries Limited has published newspaper advertisements on July 28, 2026, and posted on social media regarding a Special Window for the transfer of physical shares. This window is open for one year from February 5, 2026, to February 4, 2027, for shares sold or purchased before April 1, 2019, including those previously rejected or returned due to documentation issues.
Sun Pharmaceutical Industries Limited announced on July 27, 2026, that its partner Philogen has resubmitted a Marketing Authorization Application to the European Medicines Agency (EMA) for NidlegyTM. This investigational product is for the neoadjuvant treatment of adult patients with locally advanced, fully resectable melanoma. The resubmission includes updated clinical data from the Phase III PIVOTAL study with a longer median patient follow-up and additional post-hoc analyses, as well as Chemistry, Manufacturing and Controls (CMC) information to address previous questions.
On July 24, 2026, Sun Pharmaceutical Industries Limited announced that Organon & Co. stockholders approved proposals for Organon to become a wholly owned subsidiary of Sun Pharma's indirect subsidiary, Sun Pharmaceutical Holdings USA, Inc. This shareholder approval is a significant step towards completing the acquisition, which is still subject to customary closing conditions and regulatory approvals.
Sun Pharmaceutical Industries Limited received approval from the South African Health Products Regulatory Authority (SAHPRA) on July 15, 2026, to manufacture and market a generic semaglutide injection in South Africa. This product is for adults with type 2 diabetes and will be available in two strengths. South Africa is the second market, after India, where Sun Pharma has obtained approval for this generic medication.
Sun Pharmaceutical Industries Limited received approval from the South African Health Products Regulatory Authority (SAHPRA) on July 15, 2026, to manufacture and market a generic semaglutide injection in South Africa. This product is for adults with type 2 diabetes and will be available in two strengths. South Africa is the second market, after India, where Sun Pharma has obtained approval for this generic medication.
Sun Pharmaceutical Industries Limited will announce its first quarter financial results for the period ending June 30, 2026, on July 31, 2026. An earnings conference call for senior management to discuss performance and answer questions is scheduled for the same day at 06:30 pm IST. The results will be available on the company website, www.sunpharma.com.
Sun Pharmaceutical Industries Limited will announce its first quarter financial results for the period ending June 30, 2026, on July 31, 2026. An earnings conference call for senior management to discuss performance and answer questions is scheduled for the same day at 06:30 pm IST. The results will be available on the company website, www.sunpharma.com.
Sun Pharmaceutical Industries Limited has released an investor presentation for June 2026, detailing its financial performance, business operations across various segments including US Generics, India Formulations, Emerging Markets, and Rest of World. The presentation highlights the company's R&D investments, manufacturing capabilities, and corporate governance. It also provides updates on its Innovative Medicines pipeline and key deals, including the announced acquisition of Organon & Co. and the completion of the Taro merger.
Sun Pharmaceutical Industries Limited published newspaper advertisements on July 7, 2026, in the Financial Express (English and Gujarati) regarding their 34th Annual General Meeting and e-voting. Copies of these advertisements are available on the company's website.
Sun Pharmaceutical Industries Limited published newspaper advertisements on July 7, 2026, in the Financial Express (English and Gujarati) regarding its 34th Annual General Meeting and e-voting. The company also dispatched notices for the 34th AGM and the Annual Report for FY 2025-26 electronically on July 6, 2026, to shareholders with registered email addresses. The remote e-voting period is scheduled from July 27 to July 30, 2026, with a cut-off date of July 24, 2026, for determining voting eligibility.
Recent market and company developments associated with Sun Pharmaceutical Industries.
Sun Pharma wins antitrust litigation in the U.S., affirming a settlement with Pfizer regarding generic Lipitor competition.
Delhi High Court ordered Sun Pharma to seek judicial approval before launching semaglutide tablets, following a patent infringement suit by Novo Nordisk. The order requires Sun Pharma to return to court once it secures a manufacturing licence.
Business news today: Read India Business News Live. Latest Business news and updates on Finance, share market, IPO, and economy. Discover Business News Headlines, Top Financial News, and more on The Economic Times.
2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decades of growth from importing medicines to global leadership. The nation now supplies a significant portion of the world's generic medicines and vaccines. The Covid-19 pandemic further showcased the industry's manufacturing capabilities globally. Government initiatives now aim to foster innovation and high-value biopharmaceutical production.
An analysis of Q1 results show Sun Pharma and Aurobindo Pharma delivering strong growth, while Dr Reddy’s earnings were hit by lower lenalidomide sales and a semaglutide-related provision
Bajaj Broking’s Pabitro Mukherjee believes the broader market structure has turned constructive, with dips likely to attract buying interest. He recommends four top stock picks, hinting at a bullish reversal.
Brent crude fell more than 5 per cent overnight to a three-week low, slipping below $80 per barrel
India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
Q1 Results LIVE Updates: SBI Funds Management, Ather Energy, Inox India, IREDA, DOMS Industries, DLF, Escorts Kubota, CAMS, NOCIL, Nazara Tech, PNC Infra, Torrent Power, UPL, Restaurant Brands Asia, PNC Infra, KIMS, KEI Industries, Jindal Stainless, Ethos, GSK Pharma, Bluejet Healthcare, Kansai Nerolac, JM Financial, Kalpataru, Dhanuka Agritech, Texmaco Rail, are among the companies reporting their earnings today. Results reactions will come from stocks like ITC, Maruti Suzuki, Muthoot Finance, Dixon tech, and many others. Watch this space for all the LIVE Q1 results updates.
Sensex Today | Stock Market Live Updates: We are at the halfway mark of the day's trade, and the markets are trading on a strong footing, holding onto the gains. The Nifty is up over 200 points, rising above 24,600. The Nifty Bank is also higher, jumping over 530 points, rising to 57,600. ITC, Shriram Fin and IndiGo are top gainers.
Comprehensive Section Breakdown for Sun Pharmaceutical Industries
Strategic Vision: Develops, manufactures, and commercializes pharmaceutical products globally.
Category: Manufacturing
Manufactures finished oral solid dosages, injectables, liquids, and ointments marketed across cardiovascular, neuropsychiatry, gastroenterology, and anti-infective therapeutic segments.
Category: Manufacturing
Develops and commercializes proprietary, clinically differentiated medicines primarily in dermatology, ophthalmology, and oncology.
Key Products & Services: tildrakizumab • cyclosporine ophthalmic solution
Category: Manufacturing
Produces bulk chemical substances, including peptides, steroids, and cytotoxic active ingredients for captive use and export to global pharmaceutical manufacturers.
Core Thesis: A vertically integrated model balances high-volume generic production with specialized, research-intensive clinical portfolios.
• Hybrid Brand Strategy: The company bridges branded generics in emerging markets with innovative specialty medicines in regulated markets, using generics cash flow to fund specialty product development. • API Sourcing & Backward Integration: In-house API manufacturing secures raw chemical inputs for finished dosage formulations, managing costs and supply chain risks. • R&D and Product Pipeline Integration: Global research centers develop complex generic delivery mechanisms and process chemistry, transferring technology to manufacturing sites. • Therapeutic Focus (Specialty Franchise): The innovative business concentrates on dermatology, ophthalmology, and oncology, with dedicated sales representatives detailing these brands.
• Vertically integrated manufacturing operations
• Diverse portfolio of generic, branded generic, and specialty pharmaceutical products
• In-house API production capabilities
• Global research and development centers